RP 323 Opens New Pathways Of Growth For Rich Pharmaceuticals Inc (OTCBB:RCHA)

Rich Pharmaceuticals Inc (OTCBB:RCHA), a clinical-stage biotech firm focused on developing therapies in oncology, with prime concentration on treating Hodgkin’s Lymphoma and Acute Myelocytic Leukemia, highlight its 2014 significant accomplishments.

Acute myelocytic leukemia

Acute myelocytic leukemia, also termed as acute myelogenous leukemia, is the most common form of acute leukemia that attack adults. It is a fatal form of blood cancer and the bone marrow. The disease is characterized by the growth of abnormal white blood cells that build up in the bone marrow. These abnormal white blood cells interfere with the production of normal cells. It is a widespread disease affecting almost 18,000 people in the U.S. annually. Rich Pharmaceuticals Inc (OTCBB:RCHA) RP-323 that induces differentiation in primary cells activates PKC and modulates the function of various downstream cell-signaling pathways.

Hodgkin’s lymphoma

The other area where Rich Pharmaceuticals Inc (OTCBB:RCHA) is focusing is Hodgkin’s lymphoma. It is a cancer that is prevalent in two different age groups, from 15 years to 35 years and in people over 55. It is found in both sexes although males are highly affected by Hodgkin’s lymphoma. Malignant Reed Sternberg cells destroy the internal structure of the lymph nodes and gain access to major organs including spleen and liver. Chemotherapy and radiation are used routinely. However, these treatments can result in mortality and morbidity due to second malignancies. In the United States, more than 175,000 people suffer from the disease.


Rich Pharmaceuticals’ RP-323 can be termed as a phorbol ester. It is known to induce differentiation and/or apoptosis. It activates PKC that produces NF Kappa B, which can regulate the cellular activity by entering into the cell nucleus. It binds to DNA and alters the nature of the cell. It performs four functions, first induces differentiation, second induces proliferation, third is cytokine induction and last is apoptosis. The medication offers extensive scope and opportunities to Rich Pharmaceuticals Inc (OTCBB:RCHA).

Related News

Leave a Reply

Your email address will not be published. Required fields are marked *

Copyrıght 2015 All RIGHTS RESERVED.